Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease actively involved in regulating lipid homeostasis. Although PCSK9 has been shown to inhibit hepatitis C virus (HCV) entry and replication, the underlying mechanisms have not been thoroughly characterized. Moreover, whether PCSK9 regulates HCV translation and assembly/secretion has not been determined. We therefore further studied the effects of PCSK9 on the HCV life cycle. We showed that PCSK9 did not affect HCV translation or assembly/secretion. Overexpression of PCSK9 inhibited HCV replication in HCV genomic replicon cells in a dose-dependent manner and after cell culture-derived HCV (HCVcc) infection. Knocking down PCSK9 increased HCV replication. The gain-of-function (D374Y) or loss-of-function (Daa. 31-52) PCSK9 mutants for low-density lipoprotein receptor (LDLR) degradation had no effect on HCV replication, suggesting that HCV replication inhibition by PCSK9 was not due to LDLR degradation. The uncleaved ProPCSK9, but not cleaved PCSK9, down-regulated HCV replication, suggesting that the auto-cleavage of PCSK9 affected HCV replication. We also found that PCSK9 interacted with NS5A through NS5A aa. 95-215, and this region played an important role in NS5A dimerization, NS5A-RNA binding and was essential for HCV replication. More importantly, NS5A dimerization and NS5A-RNA binding were suppressed by PCSK9 upon interaction. These results suggested that PCSK9 inhibited HCV replication through interaction with NS5A. Our study should help optimize anti-HCV treatment regimen in patients with abnormal lipid profiles.
INTRODUCTION
Hepatitis C virus (HCV), which belongs to the genus Hepacivirus in the Flaviviridae family, is an enveloped positive-sense single-stranded RNA virus with seven major genotypes [1, 2] . Its genome is approximately 9.6 kb and encodes a polyprotein precursor that can be cleaved into three structural proteins: core, envelope glycoproteins E1 and E2, and seven non-structural proteins p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B [3, 4] . HCV infects a population of about 170 million worldwide and 70-80 % of exposed individuals develop into chronic infection [5, 6] . Chronic HCV infection can result in progressive liver damage, including steatosis, cirrhosis and hepatocellular carcinoma, which eventually leads to liver failure [7] . Although recently approved direct-acting antivirals have significantly improved efficacy and safety compared to traditional interferon-based therapy, regimens that are more affordable and effective for HCV infections of all genotypes and difficultto-treat patients are still challenging [8, 9] .
Proprotein convertase subtilisin/kexin type 9 (PCSK9), the ninth member in the proprotein convertase family, is primarily produced in the liver and intestine [10, 11] . It is a 72 kDa protein that is composed of a signal peptide (SP), a prodomain (PD), a catalytic domain and a C-terminal domain [10, 12, 13] . After removal of the SP by signal peptidase from preproPCSK9, the proPCSK9 is translocated to the ER, where the PD is auto-catalytically cleaved to produce mature PCSK9 (63 kDa). PD cleavage is essential for maturation and secretion of PCSK9, but cleaved PD is still associated with mature PCSK9 through hydrogen bonds, which forms a PCSK9-PD complex. After exiting the ER, the complex is routed to cis-Golgi and secreted outside of the cell [14] [15] [16] [17] . PCSK9 can down-regulate the low-density lipoprotein receptor (LDLR) by facilitating LDLR lysosomal degradation. Thus, it plays an essential role in increasing the plasma level of low-density lipoprotein cholesterol (LDLC), which is a determinant for familial autosomal dominant hypercholesterolemia [17, 18] .
Apart from the major role of PCSK9 in the regulation of LDLC homeostasis, it has been published that PCSK9 has an antiviral effect on HCV. Labonte et al. were the first to demonstrate that PCSK9 could inhibit HCV entry and subsequent replication [19] . They identified that PCSK9 markedly decreases the levels of HCV receptors LDLR and cluster of differentiation 81 at the cell surface. In a followup study, Syed et al. characterized the effect of PCSK9 on HCV replication specifically using an approach that could overcome the inhibition of HCV entry by PCSK9 [20] . They showed that PCSK9 inhibits HCV replication in HCV replicon cells and after HCV infection [20] . However, the underlying molecular mechanisms have not been studied. In addition, the effects of PCSK9 on HCV RNA translation, virion assembly and secretion have not been characterized. A thorough understanding of the modulation of the HCV life cycle by PCSK9 will provide important information not only for developing PCSK9 as an alternative and/or supplementary HCV therapy, but also for using PCSK9 inhibitors to treat cardiovascular diseases especially in hepatitis C patients.
In this paper, we further studied the role of PCSK9 in the HCV life cycle. We demonstrated that PCSK9 had no effect on HCV translation, virion assembly or secretion. PCSK9 down-regulated HCV replication with the involvement of PCSK9 auto-cleavage. Furthermore, we showed an interaction between PCSK9 and NS5A, and the interaction decreased NS5A dimerization and the RNA-binding activity of NS5A.
RESULTS
PCSK9 has no effect on HCV translation, virion assembly or secretion To study the effect of PCSK9 on HCV translation, Huh-7 cells were co-transfected with HCV-2a J6/JFH-1(p7-RLuc2A) GNN reporter RNA and vector, or plasmids expressing PCSK9 or glutathione S-transferase (GST) (as a negative control). The conserved GDD motif in NS5B polymerase is mutated to GNN, which renders this HCV RNA replication deficient [21] . Thus, Renilla luciferase activity reflects HCV RNA translation level [22] . As shown in Fig. 1 (a), the luciferase activity measured after expression of PCSK9 was similar to those after vector transfection or GST expression. The levels of NS5A protein determined by Western blotting were also similar in vector-, GST-and PCSK9-transfected cells (Fig. S1 , available in the online version of this article), confirming the luciferase reporter data. These results suggested that PCSK9 did not affect HCV translation.
To study the effect of PCSK9 on HCV virion assembly, Huh-7-HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells were transfected with vector, GST-or PCSK9-expressing plasmids. Cells were washed to remove secreted HCV virions, and lysed in fresh media. After three cycles of freezing and thawing, cell debris was removed and the supernatants were used to infect naïve Huh-7.5 cells. Then, the luciferase assay was performed to determine the amounts of virions assembled in the initial genomic replicon cells. As shown in Fig. 1(b) , PCSK9 expression did not cause significant change in luciferase activity compared to vector or GST expression, indicating that PCSK9 did not affect virion assembly. To determine the effect of PCSK9 on HCV virion secretion, we used the supernatant of HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells which were transfected with vector, GST-or PCSK9-expressing plasmids to infect naïve Huh-7.5 cells. Similarly, luciferase assay results showed that PCSK9 did not alter virion secretion (Fig. 1c) . The expression of GST and PCSK9 proteins was confirmed by Western blotting (Fig. 1d ).
Taken together, these results indicated that PCSK9 did not affect HCV translation, virion assembly or secretion.
PCSK9 overexpression inhibits HCV replication in a dose-dependent manner Although PCSK9 has been shown to inhibit HCV replication [20] , the mechanism has not been well characterized. With a focus on the mechanism, we studied the effect of PCSK9 on HCV replication. To this end, HCV-2a J6/JFH-1 (p7-RLuc2A) reporter genomic replicon cells were transfected with plasmid vector, GST-or PCSK9-expressing plasmids, and HCV RNA levels were measured by reverse transcription quantitative real-time PCR (RT-qPCR). As shown in Fig. 2(a) , the HCV RNA level in PCSK9-transfected cells significantly reduced compared to vector-or GST-transfected cells, suggesting that PCSK9 down-regulated HCV replication. Consistently, the NS5A levels also decreased in PCSK9-transfected cells (Fig. S2a) . Since PCSK9 does not affect HCV translation, HCV protein level should reflect the degree of HCV replication. To demonstrate whether the levels of PCSK9 protein were inversely correlated with HCV replication, HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells were transfected with increasing amounts of PCSK9-expressing plasmid. Results in Fig. 2(b) showed a dose-dependent decrease in Renilla luciferase activity with increasing levels of PCSK9, as shown in Fig. 2(c) . Correspondingly, the levels of NS5A gradually reduced as PCSK9 gradually increased (Fig. S2b) . These results indicated that PCSK9 inhibited HCV replication in a dose-dependent manner. Next, we studied the effect of PCSK9 on HCV replication after HCV infection. Huh-7.5 cells were infected with cell culture-derived HCV (HCVcc) before being transfected with plasmid vector, GST-or PCSK9-expressing plasmids, which eliminated the effect of PCSK9 on HCV entry. The luciferase activity in PCSK9-transfected cells showed significant down-regulation compared to vector-or GST-transfected cells, indicating that PCSK9 inhibited HCV replication after HCV infection (Fig. 2d ).
PCSK9-induced LDLR degradation does not affect HCV replication
As published in other work, LDLR plays an important role in HCV replication because an LDLR-specific antibody that blocks LDLR supresses HCV replication [23] . Since one of the major functions of PCSK9 is to down-regulate LDLR, we investigated whether LDLR degradation by PCSK9 was involved in HCV replication inhibition by PCSK9. We took advantage of two PCSK9 mutants that have been characterized as either gain-of-function (D374Y) or loss-of-function (Daa. 31-52) mutants in terms of LDLR degradation. D374Y PCSK9 increases LDLR degradation, while Daa. 31-52 PCSK9 decreases LDLR degradation. Both mutants still retain the capacity for auto-cleavage and secretion [12, 24, 25] . We transfected HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells with plasmids expressing PCSK9, wild-type, D374Y or Daa. 31-52, and measured HCV replication. The results showed that D374Y PCSK9 and Daa. 31-52 PCSK9 expression had similar inhibitory effects on HCV replication in comparison to wild-type PCSK9 (Fig. 2e for RLuc activities and S2c for NS5A levels). The expression of wild-type and mutant PCSK9 proteins was demonstrated by Western blotting (Fig. 2f) . To confirm the effects of these two PCSK9 mutants on LDLR degradation, we transfected HEK293T cells with these PCSK9 plasmids and collected the supernatants from transfected HEK293T cells to treat Myc-LDLR-transfected Huh-7 cells as per an established protocol [26] . Fig. 2(g) showed that, in comparison to wildtype PCSK9, D374Y PCSK9 increased, while Daa. 31-52 PCSK9 decreased LDLR degradation. These results suggested that HCV replication inhibition by PCSK9 was not due to LDLR degradation.
PCSK9 knockdown increases HCV replication
To further confirm the role of PCSK9 in HCV replication, we knocked down endogenous PCSK9 in HCV-2a J6/JFH-1 (p7-RLuc2A) reporter genomic replicon cells by PCSK9-specific shRNA and measured HCV replication. As shown in Figs 3(a) and S3(a), knocking down PCSK9 resulted in significantly higher luciferase activity and NS5A level in comparison to control or GFP knockdown. The level of PCSK9 protein after shRNA knockdown was demonstrated by Western blotting (Fig. 3b) . To confirm that the observed changes in HCV replication after PCSK9 knockdown were indeed due to the altered PCSK9 levels, we generated a PCSK9-expressing plasmid with the shRNA target sequence mutated (DshRNA PCSK9). We co-transfected HCV-2a J6/ JFH-1(p7-RLuc2A) reporter genomic replicon cells with control or PCSK9 shRNA, together with plasmids expressing wild-type or DshRNA PCSK9. As expected, when cotransfecting control or PCSK9 shRNA with wild-type PCSK9, HCV RNA replication represented by luciferase activity and NS5A level in PCSK9-knockdown cells increased compared to control cells (Figs 3c and S3b). When overexpressing DshRNA PCSK9 that could not be knocked down by the shRNA, PCSK9 shRNA no longer upregulated HCV replication compared to control shRNA (Figs 3c and S3b). PCSK9 levels in these cells were demonstrated in Fig. 3(d) . These results demonstrated that HCV RNA replication was indeed negatively regulated by PCSK9.
ProPCSK9 down-regulates HCV replication
Two forms of PCSK9 are present in cells: proPCSK9 and cleaved PCSK9 [27] . Since these two forms were consistently detected in our experiments (Figs 1-3 ), we were interested in determining which form contributed to HCV replication inhibition. To this end, we generated plasmids expressing either proPCSK9 (Q152H PCSK9) or cleaved PCSK9 by deleting the PD (DPD PCSK9). The Q152H mutant has an amino acid substitution at the cleavage site, which suppresses PCSK9 auto-cleavage and secretion [28] . HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells were transfected with these plasmids. Plasmid vector or wild-type PCSK9-expressing plasmid were included as controls. Luciferase assay and Western blotting results showed that Q152H PCSK9 down-regulated HCV replication, but DPD PCSK9 did not (Figs 4a and S4a). Fig. 4 (b) confirmed that Q152H PCSK9 could not be auto-cleaved and only proPCSK9 was detected, while DPD PCSK9 expressed only the cleaved form. These results indicated that only proPCSK9 functioned in inhibiting HCV replication.
To further confirm that auto-cleavage of PCSK9 played a role in regulating HCV replication, we performed a competition experiment by co-transfecting wild-type PCSK9 with increasing amounts of DPD PCSK9 into HCV-2a J6/JFH-1 (p7-RLuc2A) reporter genomic replicon cells. Fig. 4 (d) showed that proPCSK9 gradually increased with the increasing levels of DPD PCSK9, suggesting that cleaved PCSK9 inhibited the auto-cleavage of proPCSK9. Correspondingly, the down-regulation of HCV replication gradually enhanced with the increasing levels of proPCSK9 (Figs 4c and S4b). It implied that the inhibition of PCSK9 auto-cleavage down-regulated HCV replication. To rule out the possibility that increasing cleaved PCSK9 levels affected HCV replication, luciferase activity was determined in HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells after transfecting with increasing amounts of DPD PCSK9-expressing plasmid. No difference in luciferase activity was detected (Fig. 4e) . Similarly, levels of NS5A protein were not affected (Fig. S4c) . Expression of DPD PCSK9 was shown in Fig. 4 
(f).
Taken together, these results indicated that the inhibitory effect of PCSK9 on HCV replication might be negatively regulated by its auto-cleavage.
PCSK9 interacts and co-localizes with HCV NS5A
Next, we were interested in investigating how PCSK9 supressed HCV replication. We reasoned that interaction between PCSK9 and HCV proteins might be a mechanism for PCSK9 to regulate HCV replication. NS5A is a phosphorylated zinc-metalloprotein required for RNA replication [29] . Approximately 130 cellular proteins have been identified to interact with NS5A and the interactions often affect HCV replication [29] [30] [31] . We therefore examined whether there is an interaction between PCSK9 and NS5A, thereby modulating HCV replication. For this purpose, we co-transfected HEK293T cells with Flag-tagged PCSK9 and Myc-tagged NS5A before the co-immunoprecipitation (co-IP) assay was performed. Plasmid vector and GST-expressing plasmid were used as negative controls. As shown in HEK293T and Huh-7 cell lysates were used in Western blotting with Flag, Myc and b-actin antibodies. LDLR expression was indicated by normalizing band intensities of LDLR to b-actin. Statistical differences between samples were demonstrated as follows: * if P<0.05, ** if P<0.01, **** if P<0.0001, or NS for not significant. Fig. 5(a, b) , while no GST was present in the immuoprecipitates, PCSK9 and NS5A were co-immunoprecipitated, suggesting an association between PCSK9 and NS5A. Fig. S5 confirmed that Flag-tagged PCSK9 or Myc-tagged NS5A could not be pulled down by the Protein G Dynabeads used in immunoprecipitation. We then determined whether PCSK9 and NS5A directly interacted with each other using purified PCSK9 and NS5A proteins in the co-IP assay. Purified HCV core and red fluorescent protein (RFP) were used as positive and negative controls for interacting with NS5A, respectively, because an interaction between core and NS5A has been reported [32, 33] . The results showed that NS5A could interact with PCSK9 or core, but not RFP, indicating a direct interaction between PCSK9 and NS5A (Fig. 5c) . Next, we examined the interaction in Huh-7-RLuc-HCV-2a JFH-1 NS3-NS5A Flag -NS5B subgenomic replicon (SGR) cells by transfecting with plasmids expressing V5-tagged PCSK9 or GST. Fig. 5(d) showed that PCSK9, but not GST, could interact with NS5A in HCVreplicating cells. We noticed that NS5A interacted with proPCSK9, but not the cleaved PCSK9 (Fig. 5b, d ). To further confirm this observation, HEK293T cells were cotransfected with plasmids expressing Myc-tagged NS5A and Flag-tagged wild-type, or DPD PCSK9 (cleaved PCSK9). Interestingly, although there was an interaction between NS5A and DPD PCSK9, it appeared that NS5A only bound to the proPCSK9 form when both proPCSK9 and cleaved PCSK9 were present after expressing wild-type PCSK9 because only the proPCSK9 was immunoprecipitated by NS5A (Fig. S6) . These results suggested that NS5A preferentially interacted with proPCSK9.
To investigate whether PCSK9 co-localized with NS5A, Huh-7 cells were co-transfected with plasmids expressing PCSK9 and NS5A, and the subcellular localization was analysed by an immunofluorescence assay. Cell nuclei and lipid droplets were also stained. As shown in Fig. 5(e) , both PCSK9 and NS5A proteins localized in the cytoplasm with substantial overlap with the lipid droplet staining. More importantly, co-localization of PCSK9 and NS5A could be detected.
Taken together, these results indicated that PCSK9 directly interacted and co-localized with HCV NS5A.
Mapping NS5A amino acid sequences mediating PCSK9 interaction NS5A consists of an N-terminal amphipathic helix (AH) and three structural domains I, II and III that are separated by low-complexity sequences (LCSs) (Fig. 6a) [3] . To determine which NS5A domain was involved in the interaction with PCSK9, we constructed plasmids expressing different domain truncated NS5A mutants and performed the co-IP assay. PCSK9 could interact with DAH NS5A, domain I-LCS I, domain I, AH-domain I-LCS I, but not with domain II-LCS II, domain II or domain III (Fig. 6b) , which suggested that domain I (aa. 35-215) was responsible for PCSK9 binding. Then we investigated the region within domain I that could interact with PCSK9. We constructed plasmids expressing different truncated NS5A domain I mutants and used them in the co-IP assay. Results showed that the full domain I (aa. 35-215) or aa. 95-215 could, while aa. 155-215 could not, bind to PCSK9 (Fig. 6c) . These results led us to speculate that aa. 95-154 of domain I was the binding region for PCSK9. In efforts to confirm this assumption, we generated plasmids expressing aa. 95-154 or aa. 155-215 and performed the co-IP assay. Interestingly, neither protein could be immunoprecipitated by PCSK9, although the input proteins were readily detectable (Fig. 6d) . These results indicated that NS5A domain I aa. 95-215 was essential for PCSK9 binding. In order to verify this finding in the context of full-length NS5A, co-IP assay was performed using plasmids that had same deletions as in domain I. The co-IP results showed that full-length NS5A or NS5A with aa. 35-94 deletion could interact with PCSK9, but NS5A with aa. 95-215 deletion could not interact with PCSK9 (Fig. 6e) . These results collectively indicated that PCSK9 interacted with NS5A through aa. 95-215 in domain I.
NS5A aa. 95-215 plays an important role in NS5A dimerization, NS5A-RNA binding and HCV replication A crystal structure study of HCV-1b (Con1) NS5A domain I revealed that the NS5A dimer interface is composed of residues 92-99, 112-116, 139-143, 146-149 and 160-161 and half of these contact residues are highly conserved [34] . Crystallization of HCV-1a (H77) NS5A domain I showed two dimeric forms with residues 97-99, 112-115, 149 and 160-161, or 74-78 and 83-84 in the dimer contact surface [35] . Four conserved cysteines (Cys39, Cys57, Cys59 and Cys80) that consist of zinc-binding motif are also critical for HCV-1b (Con1) NS5A dimer formation [36] . Since the majority of these reported essential residues for NS5A dimerization are within aa. 95-215, we speculated that HCV-2a NS5A aa. 95-215 was also essential for NS5A dimerization. To test this hypothesis, we carried out a split luciferase complementation assay (SLCA) to study NS5A dimerization. SLCA is based on reconstituted luciferase activity of non-functional N-and C-terminal fragments of luciferase by fusing these fragments to interacting proteins. Protein-protein interaction can bring these two fragments of luciferase in proximity to restore the enzymatic activity [37] . We constructed plasmids expressing fusion proteins of aa. 1-229 (LN) or aa. 230-311 (LC) of Renilla luciferase with full-length NS5A or NS5A with aa. 95-215 deletion (Fig. 7a) . SLCA results showed that the LN-NS5A/LC-NS5A pair exhibited a more than 26-fold increase in luciferase activity compared to controls (LN/LC, LN/LC-NS5A and LN-NS5A/LC pairs), which validated the SLCA approach for studying NS5A dimerization (Fig. 7b) . More importantly, although the LN-Daa. 95-215 NS5A/LC-NS5A pair showed an approximately three-fold increase in luciferase activity compared to controls (LN/LC, LN/LC-NS5A and LN-Daa. 95-215 NS5A/LC pairs), the luciferase activity of LN-NS5A/LC-Daa. 95-215 NS5A and LN-Daa. 95-215 NS5A/LC-Daa. 95-215 NS5A pairs did not have a significant difference compared to their corresponding controls (Fig. 7b) . When Daa. 95-215 NS5A was used in SLCA, the luciferase activities were reduced to the basal level with the exception of the LN-Daa. 95-215 NS5A/LC-NS5A pair that showed an approximately three-fold increase (Fig. 7b) . Protein expression was demonstrated by Western blotting (Fig. 7c) . These results indicated an important role of aa. 95-215 in NS5A dimerization.
Lim et al. demonstrated that NS5A dimerization is required for its RNA-binding activity as well as HCV replication [36] . Therefore, we investigated whether NS5A with aa. 95-215 deletion affected NS5A-RNA binding or HCV replication. NS5A-RNA binding was determined by an RNA and Li and Liu, Journal of General Virology 2018;99: [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] protein immunoprecipitation (RIP) assay as per an established protocol [38] . HCV-2a J6/JFH-1(p7-RLuc2A) genomic replicon cells were transfected with plasmids expressing Myc-tagged wild-type NS5A or Myc-tagged Daa. 95-215 NS5A. Real-time qRT-PCR assay demonstrated that significantly less HCV RNA was immunoprecipitated by Daa. 95-215 NS5A compared to wild-type NS5A (Fig. 7d) , which suggested that NS5A-RNA binding was decreased in the absence of aa. 95-215. To demonstrate the specificity of the RIP assay, we also measured b-glucuronidase (GUSB) RNA levels in immunoprecipitated RNA, which were not detectable (data not shown). Fig. 7(e) confirmed the presence of Myc-tagged NS5A proteins in the immunoprecipitates.
Next, we examined the effect of NS5A with aa. 95-215 deletion on HCV replication. We transfected Huh-7 cells with HCV SGR reporter RNA with the aa. 95-215 of NS5A deleted (RLuc-HCV-2a JFH-1 NS3-Daa. 95-215 NS5A Flag -NS5B), and performed luciferase assay in a time course. Wild-type and replication-deficient HCV SGR RNAs were used as positive and negative controls, respectively. Fig. 7(f) showed that HCV SGR RNA with NS5A aa. 95-215 deletion exhibited similar luciferase activities as the replication-deficient SGR RNA at all time points, suggesting NS5A aa. 95-215 was essential for HCV replication.
Taken together, these results indicated that aa. 95-215 of NS5A was involved in NS5A dimerization, NS5A-RNA binding, and essential for HCV replication.
NS5A dimerization and NS5A-RNA binding are inhibited through the interaction with PCSK9 We next investigated whether the interaction between PCSK9 and NS5A affected NS5A dimerization and NS5A-RNA binding, thereby inhibiting HCV replication. To determine the effect of PCSK9-NS5A interaction on NS5A dimerization, SLCA was carried out by co-transfecting plasmids expressing Flag-tagged PCSK9, LN-NS5A and LC-NS5A. Plasmid vector and GST-expressing plasmid were used as negative controls. Fig. 8(a) showed that PCSK9 expression significantly reduced NS5A dimerization. In contrast, PCSK9 had no effect on the luciferase activity after LN-Daa. 95-215 NS5A/LC-NS5A co-transfection (Fig. 8b) . To test the effect of PCSK9-NS5A interaction on RNAbinding activity of NS5A, we performed the RIP assay by co-transfecting HCV-2a J6/JFH-1(p7-RLuc2A) genomic replicon cells with plasmids expressing Flag-tagged PCSK9, and Myc-tagged NS5A, wild-type or Daa. 95-215. Plasmid vector and GST-expressing plasmid were used as negative controls. In comparison to vector or GST, expression of PCSK9 resulted in significantly less HCV RNA in the Myc immunoprecipitates, suggesting that the RNA-binding activity of NS5A was suppressed in the presence of PCSK9 (Fig. 8c) . In contrast, there was no significant difference in immunoprecipitated HCV RNA levels among cells co-transfected with plasmids expressing Daa. 95-215 NS5A and vector, GST or PCSK9 (Fig. 8d) . Fig. 8(e, f) confirmed the interaction between PCSK9 and NS5A through aa. 95-215. These results indicated that the interaction between PCSK9 and NS5A inhibited NS5A dimerization and HCV RNA binding to NS5A, and PCSK9 no longer affected these NS5A properties when the interaction was disrupted.
DISCUSSION
The antiviral effect of PCSK9 on HCV has not been thoroughly characterized. Given the tremendous interest of using PCSK9 as a drug target in a variety of clinical conditions, we further studied the effect of PCSK9 on the HCV life cycle.
PCSK9 is actively involved in modulating lipid homeostasis [39] . A previous study from our group showed that sterol regulatory element-binding proteins, transcriptional factors for lipogenesis, regulate HCV RNA translation [40] . HCV virion assembly and secretion are also closely connected with the host lipoprotein assembly and secretion pathways [41] . One would therefore assume a possible role for PCSK9 in these processes. Interestingly, however, our results showed that PCSK9 did not affect HCV translation, virion assembly or secretion (Figs 1 and S1 ). This may suggest that the pathways regulating HCV translation and assembly/ secretion are separate from those modulated by PCSK9.
Although PCSK9 has been demonstrated to down-regulate HCV replication, the molecular mechanisms are not known. We therefore focused our subsequent study on this aspect. We first demonstrated that PCSK9 impeded HCV replication in genomic replicon cells in a dose-dependent manner (Figs 2b and S2b) . Furthermore, by shRNA knockdown and in combination with expressing an shRNA-resistant PCSK9, we demonstrated the specificity of the observed changes in HCV replication (Figs 3 and S3) . We also showed that PCSK9 inhibited HCV replication after HCV infection (Fig. 2d) . These results reinforced and extended previously recognized inhibitory effects of PCSK9 on HCV replication.
Because of the role of PCSK9 in LDLR degradation and the importance of LDLR in HCV replication, we reasoned that LDLR degradation might be involved in PCSK9-induced HCV replication inhibition. To our surprise, neither the gain-of-function mutant nor the loss-of-function mutant of PCSK9 showed a significant difference in HCV replication inhibition compared to wild-type PCSK9 (Figs 2e, g and S2c). These results suggested that the inhibitory effect of PCSK9 on HCV replication was independent of LDLR degradation. Our data extended a previous study by also including a loss-of-function mutant of PCSK9 [20] .
Both proPCSK9 and cleaved PCSK9 are present in cells. We showed only proPCSK9 could regulate HCV replication and cleaved PCSK9 did not (Figs 4 and S4) . On the other hand, increasing the levels of cleaved PCSK9 was associated with decreasing auto-cleavage of the proPCSK9 and thus resulting in increased proPCSK9 levels (Fig. 4d) . It implied a negative feedback loop between proPCSK9 and cleaved PCSK9. The underlying mechanism for the differential effects on regulating HCV replication by two PCSK9 forms is not clear. An interesting hypothesis would be that the proteolytic cleavage of PCSK9 is involved in regulating HCV replication that should be studied further. This mode of action is not unprecedented since La protein cleavage has been shown to play a role in regulating HCV [42] .
Since protein-protein interaction is one of the mechanisms for PCSK9 to exert its functions, we hypothesized that PCSK9 might interact with HCV proteins to regulate HCV replication. Considering that NS5A has been shown to interact with numerous cellular proteins and many of which play a role in HCV replication, we focused on NS5A. Indeed, we discovered that PCSK9 directly interacted and co-localized with NS5A (Fig. 5) . Moreover, we demonstrated an interaction between PCSK9 and NS5A in HCVreplicating cells (Fig. 5d) . We would like to point out that these experiments were performed after ectopic expression of PCSK9. Our attempts to demonstrate an interaction between NS5A and endogenous PCSK9 were not successful probably because the endogenous PCSK9 level was too low to be detected in Western blotting after immunoprecipitation (data not shown).
We next identified that NS5A domain I aa. 95-215 was essential to interact with PCSK9 (Fig. 6) . NS5A domain I contributes to NS5A dimerization and RNA binding, which is a determinant for HCV replication [3, 43] . Therefore, we studied the role of NS5A domain I aa. 95-215 in NS5A biological functions. Fig. 7 showed aa. 95-215 deletion impaired NS5A dimerization, NS5A-RNA binding and had a lethal effect on HCV replication. More importantly, we demonstrated that PCSK9 decreased NS5A dimerization and NS5A-RNA binding (Fig. 8) . However, when the interaction between PCSK9 and NS5A was interrupted by deleting NS5A aa. 95-215, PCSK9 no longer affected these properties (Fig. 8) . Our results strongly suggested that HCV replication inhibition by PCSK9 could result from disrupting NS5A dimerization and NS5A-RNA binding through protein-protein interaction.
A previous study showed that HCVcc-2a infection is associated with reduced intracellular PCSK9 levels in Huh-7 cells [20] . Taking the inhibitory effect of PCSK9 on HCV replication into consideration, it seems logical for HCV to downregulate the PCSK9 level. However, clinical studies have demonstrated a much more complex picture. It has been reported that significantly higher plasma PCSK9 concentrations are measured in HCV-1 patients compared to HCV negative population, while plasma PCSK9 concentrations in HCV-3 patients are significantly lower. Moreover, there is no correlation between PCSK9 concentration and total cholesterol or LDLC levels in HCV-1 or HCV-3 patients, whereas such a correlation is shown in HCV negative population [44] . It indicates that HCV disrupts LDLC homeostasis and PCSK9 expression as well as plasma PCSK9 concentration in a genotype-specific manner. HCV treatment is more effective in patients with high plasma LDLC level [45] . Given the role of PCSK9 in inhibiting HCV entry and replication and increasing plasma LDLC level, elevating PCSK9 level can be considered as a means to improve the efficacy of treating HCV infection. However, high PCSK9 level is associated with hypercholesterolemia and PCSK9 concentrations are different according to HCV genotypes. As such, PCSK9 may be selectively used for anti-HCV treatment according to the infecting genotype and the antiviral effect and hypercholesterolemia of PCSK9 should be balanced.
In summary, we have demonstrated that PCSK9 did not affect HCV translation, virion assembly or secretion. PCSK9 inhibited HCV replication in a dose-dependent manner. The interaction between NS5A and PCSK9 suppressed NS5A dimerization and RNA-binding activity of NS5A, which might contribute to HCV replication inhibition. This study should improve the understanding of the antiviral effect of PCSK9 on HCV and help optimize anti-HCV regimens.
METHODS Plasmids and in vitro transcription
Wild-type and replication-deficient pFLneo-J6/JFH-1(p7-RLuc-2A) plasmids containing the full-length HCV-2a J6/ JFH-1 genomic sequence with an internal Renilla luciferase reporter gene were obtained from Dr Charles Rice [21] . Genomic plasmid pFLneo-J6 core Flag /JFH-1(p7-RLuc-2A) and SGR plasmid RLuc-HCV-2a JFH-1 NS3-NS5B were described previously [46] . A Flag-tag sequence was inserted in the NS5A coding region in the SGR backbone as previously described [47] , resulting in plasmid RLuc-HCV-2a JFH-1 NS3-NS5A
Flag -NS5B. The coding sequence for the aa. 95-215 of NS5A was deleted to give rise to RLuc-HCV2a JFH-1 NS3-Daa. 95-215 NS5A Flag -NS5B. A replicationdeficient SGR was generated by introduction of GNN mutation in NS5B, generating plasmid RLuc-HCV-2a JFH-1 NS3-NS5A
Flag -NS5B GNN. To generate plasmids expressing HCV-2a JFH-1 NS5A or GST with a Flag-tag, the respective coding sequences were amplified by PCR and cloned into the pEF vector. Plasmids expressing NS5A domains and different truncations with a Myc-tag were also generated. Plasmids expressing PCSK9 and its individual domains with a C-terminal V5-tag were received from Dr Daping Fan [12, 48] . Using these plasmids as templates, we generated plasmids expressing PCSK9 and DPD PCSK9 with a Flag-tag. Plasmids expressing Flag-tagged wild-type, D374Y or Daa. 31-52 mutant PCSK9 were received from Dr Thomas Lagace [24] . The PCSK9 Q152D mutant was generated by site-directed mutagenesis. To generate a plasmid expressing LDLR with a Myc-tag, the coding sequence of LDLR was amplified by PCR using a human LDLR cDNA (Transomic) as the template and cloned into the pEF vector. To acquire purified proteins from E. coli, the coding sequences for HCV-2a JFH-1 NS5A or PCSK9 were cloned into the pT7 His 6 -SUMO vector. HCV-2a J6 core-and RFPexpressing plasmids in the pT7 His 6 -SUMO vector were described previously [46] . The pLKO.1 lentiviral plasmid expressing PCSK9-specific shRNA with the target sequence 5¢-TACACACGTGTTGTCTACGGC-3¢ was purchased from Dharmacon/GE Healthcare. Non-silencing control or GFP siRNA-encoding pLKO.1 lentiviral plasmids were Addgene plasmids 10 879 and 12273, respectively. To generate an shRNA-resistant PCSK9 cDNA without changing the amino acid sequence, the shRNA target sequence was Cell lines, transfection, luciferase assay and Western blotting Huh-7, Huh-7.5 and human embryonic kidney HEK293T cells were cultured in Dulbecco's modified Eagle's medium (MilliporeSigma) supplemented with 10 % (v/v) FBS (MilliporeSigma) at 37 C and 5 % CO 2 . Huh-7-HCV-2a J6/JFH-1 (p7-RLuc2A) reporter genomic replicon, Huh-7-HCV-2a J6 core Flag /JFH-1(p7-RLuc-2A) reporter genomic replicon and Huh-7-RLuc-HCV-2a JFH-1 NS3-NS5A
Flag -NS5B SGR cells were generated as previously described [46, 49] . Cells were transfected with plasmid DNA and HCV reporter RNA using calcium phosphate or the jetPEI reagent (Polyplus). For the luciferase assay, cells were lysed in Passive Lysis Buffer (Promega) and luciferase activity was measured using Luciferase Assay System (Promega) by GloMax 20/20 Luminometer (Promega) according to the manufacturer's protocol. Luciferase activity was normalized to total protein concentrations which were determined by a Bradford protein assay (Bio-Rad). For Western blotting, cells were lysed in SDS sample buffer. Cell lysates were subjected to SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked with 5 % skim milk in PBS for 1 h at room temperature and then incubated with indicated primary antibodies overnight at 4 C. After incubating with infrared dye-labelled secondary antibodies for 1 h at room temperature, the blots were scanned using Odyssey CLx Imaging System (Li-Cor Biosciences). These antibodies were used: Flag-tag (MilliporeSigma), Myc-tag, V5-tag and b-actin (Cell Signaling Technology), His 6 -tag (Qiagen), NS5A [50] , IRDye 800CW goat anti-mouse IgG and IRDye 680RD goat anti-rabbit IgG (Li-Cor Biosciences).
RT-qPCR
Total RNA was extracted from cells using TRIzol (Thermo Fisher Scientific) and digested with DNase I (Thermo Fisher Scientific). Then RNA was reverse transcribed into cDNA by SuperScript II Reverse Transcriptase (Thermo Fisher Scientific). RT-qPCR was carried out by iQ5 real-time PCR detection system (Bio-Rad) using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) with primers HCV-FD (5¢-AGAGCCATAGTGGTCTGCGGAAC-3¢) and HCVRev (5¢-CCTTTCGCAACCCAACGCTACTC-3¢). HCV RNA levels were normalized with house-keeping gene GUSB RNA levels using primers GUSB-FD (5¢-GGTGC TGAGGATTGGCAGTG-3¢) and GUSB-Rev (5¢CGCAC TTCCAACTTGAACAGG'À3) by the 2 -DDCt method [46] .
HCV infection, virion assembly and secretion assay
For HCV infection, cell culture-derived HCV (HCVcc) was collected from the supernatant of Huh-7-HCV-2a J6 coreFlag /JFH-1(p7-RLuc-2A) reporter genomic replicon cells and concentrated using Amicon Ultra-15 Centrifugal Filter Units (MilliporeSigma). Virus titre was determined as per an established protocol [51] . Naïve Huh-7.5 cells were infected with HCVcc at an m.o.i. of 0.05 for 4 h and fresh media was replaced. To examine the effect of PCSK9 on HCV virion assembly, HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells were transfected with vector, GST-or PCSK9-expressing plasmids. After 48 h, cells were washed and harvested in fresh media, followed by three cycles of freezing and thawing. Cell debris was removed and the supernatants were used to infect naïve Huh-7.5 cells for 4 h. Luciferase assay was performed 72 h after infection. To examine the effect of PCSK9 on HCV virion secretion, HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells were transfected with vector, GST-or PCSK9-expressing plasmids. After 48 h, the supernatants were collected and concentrated using Amicon Ultra-15 Centrifugal Filter Units. Naïve Huh-7.5 cells were infected for 4 h and luciferase assay performed 72 h after infection. Luciferase activity was normalized to HCV RNA levels of vector-, GST-or PCSK9-transfected HCV-2a J6/JFH-1(p7-RLuc2A) reporter genomic replicon cells and total protein concentrations.
Co-IP and RIP assays
For the co-IP assay, cells were lysed in a lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and 1 % Triton X-100) supplemented with protease inhibitor cocktail (Roche) at 4 C. Cell lysates were immunoprecipitated with indicated antibodies using Dynabeads Protein G (Thermo Fisher Scientific) according to the manufacturer's protocol. Immunoprecipitated proteins were eluted in 2ÂSDS sample buffer and then subjected to SDS-PAGE and Western blotting. For the RIP assay, cells were lysed in a lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and 1 % Triton X-100) supplemented with protease inhibitor cocktail, 50 µg ml À1 BSA, 10 µg ml À1 yeast tRNA (Thermo Fisher Scientific) and 200 U ml À1 RNaseOUT (Thermo Fisher Scientific) at 4 C. Cell lysates were immunoprecipitated with indicated antibodies using Dynabeads Protein G. Immunoprecipitated RNA was extracted using TRIzol and then subjected to RT-qPCR.
Protein expression and purification E. coli BL21 (DE3) strain was transformed with His 6 -tagged HCV core, NS5A, PCSK9 or RFP expressing plasmids and cultured in LB media at 37 C until OD 595nm reached 0.5. Then 0.1 mM IPTG (Thermo Fisher Scientific) was added and the culture was incubated overnight at 21 C. The expressed proteins were purified by nickel-nitrilotriacetic acid agarose (Qiagen) according to the manufacturer's protocol. The purified proteins were buffer exchanged to PBS and concentrated using Amicon Ultra-15 Centrifugal Filter Units.
Immunofluorescence assay and confocal microscopy Cells in eight-well chamber slides were fixed with 4 % paraformaldehyde for 20 min. After permeabilized with 0.1 % Triton X-100 in PBS for 10 min, cells were blocked with 1 % goat serum (Thermo Fisher Scientific) in PBS for 30 min. Then cells were incubated with indicated primary antibodies for 2 h, followed by Alexa Fluor-conjugated secondary antibodies (Thermo Fisher Scientific) for 1 h. Next, cells were stained with 300 nM DAPI (Thermo Fisher Scientific) for 5 min and 0.3 mg ml À1 Oil Red O (Alfa Aesar) for 10 min as previously described [52] . After washing and air-drying, cells were mounted with ProLong antifide reagent (Thermo Fisher Scientific). All steps were performed at room temperature. Cells were visualized and pictures were taken using a Leica TCS SP5 confocal microscope (Leica Microsystems). Pearson's correlation coefficients that represent the overlap of two proteins or protein and lipid droplets were calculated using Fiji software.
Statistical analysis
All experiments were performed in triplicate and data analysed by GraphPad Prism 7. Statistical differences were determined by Student's t-test, one-or two-way ANOVA. Statistical significance was demonstrated as follows: * if P<0.05, ** if P<0.01, *** if P<0.001, **** if P<0.0001, or NS for not significant. 
